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Abstract: 
Introduction: Neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma (MANEC) in the 
gallbladder are rare. Here, we reported an unusual case of a mixed high-grade neuroendocrine carcinoma and 
adenocarcinoma, arising in a papillary adenoma with high-grade dysplasia. 
Presentation of case: The patient, a 73 year-old woman, had a cholecystectomy for chronic calculous 
cholecystitis, in which a mixed high-grade neuroendocrine carcinoma and adenocarcinoma arising in a papillary 
adenoma with high-grade dysplasia was incidentally noted. The carcinoma invaded into lamina propria, without 
any evidence of invasion into muscularis layer or perimuscular soft tissue, hence was pathologically staged as 
T1. The patient was treated with chemoradiation after cholecystectomy. Desspite the unusually low tumor stage 
at presentation of this rare tumor, there were four recurrences / metastases involving abdominal wall, an unusual 
site for this tumor, which were treated with surgery and / or chemotherapy. The patient is alive with metastatic 
disease at 45 months after initial cholecystectomy. 
Conclusion: We detail the unusual presentation of a mixed high-grade neuroendocrine carcinoma and 
adenocarcinoma arising in a papillary adenoma with high-grade dysplasia, which sheds some light on the 
clinical course of this rare tumor. 
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Introduction 
Neuroendocrine carcinomas represent 4% of all 
malignant neoplasms of the gallbladder and mixed 
adenocarcinoma and neuroendocrine carcinomas of 
the gallbladder are rarer [1, 2]. In the World Health 
Organization (WHO) 2010 classification of 
gallbladder tumors, mixed adenoneuroendocrine 
carcinomas (MANECs) are composite neoplasms 
in which areas of adenocarcinoma or squamous cell 
carcinoma intermingle with areas of 
neuroendocrine tumor or neuroendocrine 
carcinoma, each comprising at least 30% of the 
neoplasm [3]. There are isolated case reports of 
such tumors, all of which presented as a large mass 
in the gallbladder [2, 4-8]. To our knowledge, this 
is the first reported case of a mixed high-grade 
neuroendocrine carcinoma and adenocarcinoma 
arising in a papillary adenoma of the gallbladder, 
which was confined to the lamina propria and 
staged as pT1, yet displayed an aggressive course. 
Case presentation  
Our patient was a 73-year old woman with a 
remote history of breast carcinoma diagnosed 22 
years ago, for which she was treated with 
lumpectomy followed by radiation. Subsequently, 
there was no recurrence of this disease. She was an 
occasional smoker till 50 years of age, described as 
‘social smoking’ but she would also go long 
periods without smoking at all, until she finally 
quit. She underwent an elective laparoscopic 
cholecystectomy for cholelithiasis at an outside 
hospital.  
On gross examination, a 6.0 x 2.8 x 0.7 cm 
previously opened gallbladder was received with a 
2.0 cm green friable calculus as well as a separate 
1.5 x 0.6 x 0.6 cm aggregate of green grumous soft 
tissue, possibly representing a dislodged friable 
polyp. The gallbladder had a wall thickness of 0.2 
cm, and a pink velvety, grossly unremarkable 
mucosa. There was no mass or ulcerated lesion 
grossly identified in the gallbladder.  
Histologically, the polypoid tissue revealed a 
biliary type papillary adenoma with focal 
high-grade dysplasia and conventional invasive 
moderately differentiated adenocarcinoma, which 
comprised approximately 30% of the entirely 
submitted tumor. The rest of the polyp (70%) was 
composed of solid sheets and cords of small 
mononuclear cells with high nuclear: cytoplasmic 
(N: C) ratio, more than 60 mitoses per 10 high 
power fields and scattered areas of necrosis. 
Immunohistochemistry on the solid tumor 
component was positive for synaptophysin 
(Novocastra, 27G12, 1: 600) and chromogranin A 
(Chemicon, LK2H10, 1: 4000), but was negative 
for estrogen receptor (Novacastra, ER 6F11, 1: 35), 
progesterone receptor (Dako, PgR 1294, 1: 200) 
and mammaglobin (Biocare Medical, PM 269 AA, 
H, predilute). Pan-cytokeratin (Dako, Z0622, 1: 
100) stain was strongly positive in both 
components. Sections from the entirely submitted 
gallbladder revealed chronic cholecystitis, but no 
evidence of dysplasia or invasive carcinoma. 
Therefore the diagnosis of a mixed high-grade 
neuroendocrine carcinoma and adenocarcinoma 
arising in a papillary adenoma with high-grade 
dysplasia of gallbladder was rendered. The 
carcinoma invaded into lamina propria, without 
any evidence of invasion into muscularis layer or 
perimuscular soft tissue, hence was pathologically 
staged as T1. No lymphovascular or perineural 
invasion was identified. The cystic duct margin 
was negative for dysplasia or carcinoma. 
The patient fully recovered from the 
cholecystectomy without any complication. The 
computed tomography (CT) scan performed three 
weeks after cholecystectomy did not reveal any 
adenopathy or metastatic disease. She received 25 
fractions of external beam radiotherapy for a month 
with 5-fluorouracil and was thereafter placed on 
clinical surveillance. Eleven months after the 
cholecystectomy, a CT scan revealed an enhancing 
soft tissue nodule on the anterior abdominal wall 
 Chatterjee et al. American Journal of Cancer Case Reports 2014, 2:37-42 
  
Ivy Union Publishing | http: //www.ivyunion.org June 20, 2014 | Volume 2 | Issue 1  
Page 3 of 6 
near umbilicus, with subcutaneous and 
intraperitoneal components. She underwent a wide 
excision of the umbilical mass, which revealed a 
mixed high-grade neuroendocrine carcinoma and 
moderately differentiated adenocarcinoma, 
consistent with metastasis from primary 
gallbladder carcinoma. Six months after wide 
excision of the umbilical mass, she was found to 
have a 14 mm subcutaneous nodule in the right 
lower quadrant and underwent ultrasound guided 
fine needle aspiration (FNA), which revealed 
metastatic carcinoma, morphologically consistent 
with the patient’s known gallbladder primary. She 
subsequently underwent excision of the 
subcutaneous nodule, which showed a metastatic 
high-grade neuroendocrine carcinoma. The patient 
then received 8 cycles of chemotherapy consisting 
of gemcitabine and oxaliplatin, at doses of 1000 
mg / m2 and 100 mg / m2, respectively, given 
every other week for 4 months, which caused 
significant peripheral neuropathy. Fifteen months 
after the completion of chemotherapy, 3 new soft 
tissue nodules were identified within the anterior 
abdominal wall muscle with the largest being 3.5 
cm by CT scan and were excised, all of which 
showed mixed high-grade neuroendocrine 
carcinoma and adenocarcinoma consistent with the 
gallbladder primary. Four months later, she was 
found to have a 4 x 3.5 cm mass within the 
rectouterine pouch as well as a small nodule in the 
omentum. Due to close proximity of the tumor to 
the bladder and rectum, surgical resection was 
considered too risky and she was referred to our 
institution. Considering palliation and avoidance of 
medication which would exacerbate her peripheral 
neuropathy, she was treated with FOLFIRI 
chemotherapy (irinotecan 180mg / m2, 
5-fluorouracil 2400 mg / m2 and leucovorin 400mg 
/ m2 given over 46 hours, for 4 - 6 times over 2 
months). She responded modestly, and currently 
the patient is alive with unresectable metastatic 
disease in the omentum and cul-de-sac at 45 
months after the initial cholecystectomy. She feels 
relatively well apart from a painful peripheral 
neuropathy in both her legs secondary to previous 
oxaliplatin treatment. The only medications she is 
on is Neurontin 2 tabs p.o. at bedtime for her 
neuropathy and synthroid, 112 mcg 1 tab p.o. daily. 
Discussion  
Based on the strict definition of MANEC, at least 
30% of the tumor needs to have a malignant 
neuroendocrine component and an adenocarcinoma 
component. Therefore, both components are 
usually readily appreciable on routine H&E 
staining, with the adenocarcinoma component 
identified by gland formation, having cytologic 
features of prominent nucleoli and vesicular nuclei 
and the neuroendocrine component showing sheets, 
nests or trabeculae of cells with high 
nuclear-cytoplasmic ratio and granular chromatin. 
Immunohistochemically, the characteristic staining 
pattern is distinct in the two areas of this mixed 
tumor, which helps establish the diagnosis of this 
tumor based on the extent of staining with specific 
neuroendocrine markers. The prognosis of 
high-grade neuroendocrine carcinoma of the 
gallbladder is poor and 40 - 50% of the reported 
cases presented with disseminated disease at the 
time of diagnosis [3, 9]. Given the rarity of the 
MANEC of gallbladder, the clinical course of this 
tumor is not clear. According the WHO, MANECs 
behave as adenocarcinomas and are clinically more 
aggressive than neuroendocrine tumors [3]. 
However, a study of MANECs from the 
hepatobiliary system, including five gallbladder 
MANECs, by Harada et al suggested that the 
neuroendocrine carcinoma component defined the 
prognosis [10]. Although there is currently no data 
enumerating survival time in cases of gallbladder 
MANECs, in a study by la Rosa et al, the 5 year 
survival of gastrointestinal MANECs was 36% 
[11]. The follow up of our patient showed an 
unusual pattern of recurrence/metastasis than those 
observed in conventional gallbladder carcinomas, 
in which metastatic disease typically involves the 
lymph nodes and intraabdominal organs such as 
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liver and peritoneum [12]. The current treatment 
strategy for MANEC involves treatment of the 
more aggressive component of the tumor. In a 
MANEC containing a well differentiated 
neuroendocrine component and an adenocarcinoma 
component, it should be treated as adenocarcinoma. 
If a MANEC contains a poorly differentiated 
neuroendocrine component, it should be treated as 
a poorly differentiated neuroendocrine tumor [11]. 
According to la Rosa et al, till date, about 60 cases 
have been reported from the gastrointestinal tract. 
There is slight male prediliction, with mean age at 
diagnosis being 65 years (32- 87 years). Tumors in 
the stomach are predominantly described as 
polypoid, while from the intestines, they are 
usually large and constricting [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 A and B: H&E, 10X. Mixed adenoneuroendocrine carcinoma (MANEC) invading lamina propria. No muscle 
invasion is seen. 
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Our patient did not have liver or lymph node involvement during the course of her disease, but had multiple 
recurrences / locoregional metastases involving abdominal wall. Since the gallbladder was received in a 
previously cut-open state and the polyp was fragmented, we cannot exclude the possibility that the abdominal 
wall recurrences / metastasis may represent drop recurrence / metastasis from the initial cholecystectomy, 
which was done laparoscopically without any clinical suspicion and therefore gross inspection or lavage of 
the peritoneal cavity was not done.  
Similar to our case, association of neuroendocrine tumors with gallstones has been reported [13]. However, 
the histogenesis of neuroendocrine tumors in the gallbladder is uncertain since normal gallbladder mucosa 
does not contain neuroendocrine cells, except for the gallbladder neck region [14]. It has been postulated that 
neuroendocrine tumors of gallbladder may arise from gastric or intestinal metaplasia, which contains a 
neuroendocrine cell component, secondary to chronic inflammation; from progenitor cells with 
multidirectional differentiation potential [15], or from aberrant differentiation toward neuroendocrine cells of 
adenocarcinoma [7].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Figure 2A: H&E, 4X. Adenocarcinoma component (lower left) and high grade neuroendocrine carcinoma 
component (upper right). Figure 2B: Chromogranin immunostain, 4X. Positive staining in the neuroendocrine 
component, negative in the adenocarcinoma component. 
Conclusion 
In 2010, WHO incorporated this rare entity of 
mixed adenoneuroendocrine carcinoma (MANEC) 
of the gallbladder in their classification. There are 
few isolated reports of the case; however, the 
clinical course of this tumor is unclear. Most 
published cases presented with a large mass. In our 
case, the carcinoma was confined in a polyp 
(lamina propria, pT1) yet followed an aggressive 
course with multiple recurrence / metastasis at 
unusual sites (abdominal wall and peritoneum). 
Locoregional spread into liver or lymph nodes 
which are usual in gallbladder carcinoma, was not 
seen. 
References 
1. Albores-Saavedra J, Soriano J, 
Larraza-Hernandez O, Aguirre J, Henson DE. 
Oat cell carcinoma of the gallbladder. Hum 
Pathol. 1984, 15:639-646 
  A B 
 Chatterjee et al. American Journal of Cancer Case Reports 2014, 2:37-42 
  
Ivy Union Publishing | http: //www.ivyunion.org June 20, 2014 | Volume 2 | Issue 1  
Page 6 of 6 
2. Elahi F, Ahmadzadeh A, Yadollahzadeh M, 
Hassanpour K, Babaei M. Neuroendocrine 
tumor of the gallbladder. Arch Iran Med. 
2013, 16:123-125 
3. Bosman FT, World Health Organization., 
International Agency for Research on Cancer. 
Who classification of tumours of the digestive 
system. Lyon: International Agency for 
Research on Cancer; 2010. 
4. Al-Brahim N, Albannai R. Combined large 
cell neuroendocrine carcinoma and 
adenocarcinoma of the gallbladder. Endocr 
Pathol. 2012, 24:110-113 
5. Nishihara K, Nagai E, Tsuneyoshi M, 
Nagashima M. Small-cell carcinoma 
combined with adenocarcinoma of the 
gallbladder. A case report with 
immunohistochemical and flow cytometric 
studies. Arch Pathol Lab Med. 1994, 
118:177-181 
6. Russo S, Russo F, Maiello FM, Paolini B, 
Carrabba A, De Gregorio A. Biphasic large 
cell neuroendocrine carcinoma--pure 
mucinous carcinoma of the gallbladder 
(manec): A unique combination. Pathologica. 
2013, 104:185-189 
7. Shintaku M, Kataoka K, Kawabata K. Mixed 
adenoneuroendocrine carcinoma of the 
gallbladder with squamous cell carcinomatous 
and osteosarcomatous differentiation: Report 
of a case. Pathol Int. 2013, 63:113-119 
8. Song W, Chen W, Zhang S, Peng J, He Y. 
Successful treatment of gallbladder mixed 
adenoneuroendocrine carcinoma with 
neo-adjuvant chemotherapy. Diagn Pathol. 
2012, 7:163 
9. Kim DI, Seo HI, Lee JY, Kim HS, Han KT. 
Curative resection of combined 
neuroendocrine carcinoma and 
adenocarcinoma of the gallbladder. Tumori. 
2012, 97:815-818 
10. Harada K, Sato Y, Ikeda H, Maylee H, 
Igarashi S, Okamura A, Masuda S, Nakanuma 
Y. Clinicopathologic study of mixed 
adenoneuroendocrine carcinomas of 
hepatobiliary organs. Virchows Arch. 2012, 
460:281-289 
11. La Rosa S, Marando A, Sessa F, Capella C. 
Mixed adenoneuroendocrine carcinomas 
(manecs) of the gastrointestinal tract: An 
update. Cancers (Basel). 4:1-30 
12. Kim WS, Choi DW, You DD, Ho CY, Heo JS, 
Choi SH. Risk factors influencing recurrence, 
patterns of recurrence, and the efficacy of 
adjuvant therapy after radical resection for 
gallbladder carcinoma. J Gastrointest Surg. 
2010, 14:679-687 
13. Pitt HA, Dooley WC, Yeo CJ, Cameron JL. 
Malignancies of the biliary tree. Curr Probl 
Surg. 1995, 32:1-90 
14. Hong SM, Presley AE, Stelow EB, Frierson 
HF, Jr., Moskaluk CA. Reconsideration of the 
histologic definitions used in the pathologic 
staging of extrahepatic bile duct carcinoma. 
Am J Surg Pathol. 2006, 30:744-749 
15. Paniz Mondolfi AE, Slova D, Fan W, Attiyeh 
FF, Afthinos J, Reidy J, Pang Y, Theise ND. 
Mixed adenoneuroendocrine carcinoma 
(manec) of the gallbladder: A possible stem 
cell tumor? Pathol Int. 2011, 61:608-614 
 
 
